Postoperative Chemotherapy in Nonsmall Cell Lung Cancer: A Systematic Review

Annals of Thoracic Surgery

Volumn 81, Issue 5, 2006, Pages 1926-1936

  Alam, Naveed ^a   Darling, Gail ^b   Shepherd, Frances A ^b   Mackay, Jean A ^c   Evans, William K ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; MITOMYCIN; MITOMYCIN C; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; TEGAFUR; UFT; VINDESINE; CHEMOKINE RECEPTOR; CMKLR1 PROTEIN, HUMAN;

ANEMIA; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE SEVERITY; DRUG FATALITY; ESOPHAGITIS; EVIDENCE BASED MEDICINE; FEBRILE NEUTROPENIA; HEALTH STATUS; HUMAN; INTERMETHOD COMPARISON; LEUKOPENIA; LUNG FIBROSIS; LUNG NON SMALL CELL CANCER; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; OUTCOME ASSESSMENT; PERFORMANCE; PNEUMONIA; POSTOPERATIVE CARE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZATION; REVIEW; RISK BENEFIT ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; ADENOCARCINOMA; CONTROLLED CLINICAL TRIAL; LUNG TUMOR; META ANALYSIS; MORTALITY; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; META-ANALYSIS; RADIOTHERAPY DOSAGE; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, CHEMOKINE; SURVIVAL ANALYSIS;

EID: 33646851213     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2005.04.045     Document Type: Review

References (51)

1. Parkin D.M. Global cancer statistics in the year 2000. Lancet Oncol 2 (2001) 533-543
2. Mountain C.F. Revisions in the international system for staging lung cancer. Chest 111 (1997) 1710-1717
3. Rosell R., Felip E., Maestre J., et al. The role of chemotherapy in early non-small-cell lung cancer management. Lung Cancer 34 Suppl 3 (2001) S63-S74
4. Smythe W.R. Treatment of stage I non-small cell lung carcinoma. Chest 123 Suppl (2003) 181S-187S
5. Okawara G., Ung Y.C., Markman B.R., Mackay J.A., Evans W.K., and Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. Postoperative radiotherapy in stage II or IIIA completely resected non-small cell lung cancer. a systematic review and practice guideline. Lung Cancer 44 (2004) 1-11
6. Browman G.P., Levine M.N., Mohide E.A., et al. The practice guidelines development cycle. a conceptual tool for practice guidelines development and implementation. J Clin Oncol 13 (1995) 502-512
7. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer. a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311 (1995) 899-909
8. George S., Schell M.J., Detterbeck F.C., and Socinski M.A. Adjuvant chemotherapy for resected non-small cell carcinoma of the lung. why we still don't know. Oncologist 3 (1998) 35-44
9. Sculier J.P., Berghmans T., Paesmans M., et al. The role of chemotherapy in the treatment of non-metastatic non-small cell lung cancers. Rev Med Brux 6 (2001) 477-487
10. Hamada C., Ohta M., Wada H., et al. Efficacy of oral UFT for adjuvant chemotherapy after complete resection of non-small cell lung cancer. meta-analysis of six randomized trials in 2003 patients. [abstract]. Eur J Cancer Suppl 1 (2003) S231 A768
11. Hamada C., Ohta M., Wada H., et al. Survival benefit of oral UFT for adjuvant chemotherapy after completely resected non-small-cell lung cancer. J Clin Oncol 22 Supp 14 (2004) A7002 [meeting abstracts]
12. Bria E., Felici A., Carlini P., et al. Adjuvant chemotherapy for non-small cell lung cancer. pooled analysis of 3443 patients. Ann Oncol 15 Suppl 3 (2004) A646P [meeting abstracts]
13. Hotta K., Matsuo K., Ueoka H., Kiura K., Tabata M., and Tanimoto M. Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer. reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol 22 (2004) 3860-3867
14. Sedrakyan A., van Der Meulen J., O'Byrne K., Prendiville J., Hill J., and Treasure T. Postoperative chemotherapy for non-small cell lung cancer. a systematic review and meta-analysis. J Thorac Cardiovasc Surg 128 (2004) 414-419
15. Ichinose Y., Hara N., Ohta M., Motohiro A., Kuda T., and Aso H. Postoperative adjuvant chemotherapy in non-small cell lung cancer. prognostic value of DNA ploidy and postrecurrent survival. J Surg Oncol 46 (1991) 15-20
16. Niiranen A., Niitamo-Korhonen S., Kouri M., Assendelft A., Mattson K., and Pyrhönen S. Adjuvant chemotherapy after radical surgery for non-small-cell lung cancer. a randomized study. J Clin Oncol 10 (1992) 1927-1932
17. Feld R., Rubinstein L., Thomas P.A., and Lung Cancer Study Group. Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small-cell lung cancer. J Natl Cancer Inst 85 (1993) 299-306
18. Ohta M., Tsuchiya R., Shimoyama M., et al. Adjuvant chemotherapy for completely resected stage III non-small-cell lung cancer. Results of a randomized prospective study. J Thorac Cardiovasc Surg 106 (1993) 703-708
19. Dautzenberg B., Chastang C., Arriagada R., et al. Adjuvant radiotherapy versus combined sequential chemotherapy followed by radiotherapy in the treatment of resected nonsmall cell lung carcinoma. A randomized trial of 267 patients. Cancer 76 (1995) 779-786
20. Lee C.G., Kim J.H., Chung K.Y., et al. A prospective randomized study of postoperative adjuvant chemo-radiotherapy (CT + RT) vs. radiotherapy (RT) alone in resected stage II and IIIA non-small cell lung cancer (NSCLC). [abstract]. Int J Radiat Oncol Biol Phys 32 Suppl 1 (1995) 280 A2036
21. Keller S.M., Adak S., Wagner H., et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. New Engl J Med 343 (2000) 1217-1222
22. Mineo T.C., Ambrogi V., Corsaro V., and Roselli M. Postoperative adjuvant therapy for stage IB non-small-cell lung cancer. Eur J Cardio-Thorac Surg 20 (2001) 378-384
23. Scagliotti G.V., Fossati R., Torri V., et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst 95 (2003) 1453-1461
24. Arriagada R., Bergman B., Dunant A., et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. New Engl J Med 350 (2004) 351-360
25. Strauss G.M., Herndon J., Maddaus M.A., et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC). report of Cancer and Leukemia Group B (CALGB) protocol 9633. J Clin Oncol 22 Supp 14 (2004) A7019 [meeting abstracts]
26. Strauss GM, Herndon J, Maddaus MA, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB NSCLC: report of CALGB protocol 9633. ASCO.org virtual meeting (slide presentation on the Internet, cited July 8, 2004). Available at: http://www.asco.org/ac/1,1003,_12-002511-00_18-0026-00_19-0010290,00.asp.
27. Tada H., Tsuchiya R., Ichinose Y., et al. A randomized trial comparing adjuvant chemotherapy versus surgery alone for completely resected pN2 non-small cell lung cancer (JCOG9304). Lung Cancer 43 (2004) 167-173
28. Winton T.L., Livingston R., Johnson D., et al. A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage IB and II non small cell lung cancer (NSCLC) Intergroup JBR.10. J Clin Oncol 22 Supp 14 (2004) A7018 [meeting abstracts]
29. Winton T, Livingston R, Johnson D, et al. Phase III randomized trial of adjuvant vinorelbine and cisplatin in completely resected stage IB and II non small cell lung cancer. NCIC CTG BR.10 (SWOG JBR10, ECOG JBR10, CALGB 9795). ASCO.org virtual meeting (slide presentation on the Internet, cited July 8, 2004). Available at: http://www.asco.org/ac/1,1003,_12-002511-00_18-0026-00_19-0010198,00.asp.
30. Alam N., Shepherd F.A., Winton T., et al. Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and Intergroup trial JBR.10 and a review of the literature. Lung Cancer 47 (2005) 385-394
31. Sawamura K., Mori T., Doi O., et al. A prospective randomized controlled study of the postoperative adjuvant therapy for non-small cell lung cancer. [abstract]. Lung Cancer 4 (1988) A166 A8.2.26
32. Kuwahara O., Doi O., Mori T., et al. Postoperative adjuvant chemotherapy in non-small cell lung cancer. Results of a prospective randomized study. Jpn J Lung Cancer 32 (1992) 11-22
33. Kunishima K. A randomized controlled trial of postoperative adjuvant chemotherapy in non-small cell lung cancer. Jpn J Lung Cancer 32 (1992) 481-488
34. The Study Group of Adjuvant Chemotherapy for Lung Cancer. A randomized trial of postoperative adjuvant chemotherapy in non-small cell lung cancer (the second cooperative study). Eur J Surg Oncol 21 (1995) 69-77
35. Wada H., Hitomi S., Teramatsu T., and West Japan Study Group for Lung Cancer Surgery. Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. J Clin Oncol 14 (1996) 1048-1054
36. Wada H., Miyahara R., Tanaka F., and West Japan Study Group for Lung Cancer Surgery (WJSG). Postoperative adjuvant chemotherapy with PVM (cisplatin + vindesine + mitomycin C) and UFT (uracil + tegafur) in resected stage I-II NSCLC (non-small cell lung cancer). a randomized clinical trial. Eur J Cardio-Thorac Surg 15 (1999) 438-443
37. Xu G., Rong T., and Lin P. Adjuvant chemotherapy following radical surgery for non-small-cell lung cancer. a randomized study on 70 patients. Chin Med J 113 (2000) 617-620
38. Tada H., Yasumitu T., Iuchi K., et al. Randomized study of adjuvant chemotherapy for completely resected non-small cell lung cancer. lack of prognostic significance in DNA ploidy pattern at adjuvant setting. [abstract]. Proc Am Soc Clin Oncol 21 (2002) 313a A1250
39. Endo C., Saito Y., Iwanami H., et al. A randomized trial of postoperative UFT therapy in p stage I, II non-small cell lung cancer. North-east Japan Study Group for Lung Cancer Surgery. Lung Cancer 40 (2003) 181-186
40. Imaizumi M. A randomized trial of postoperative adjuvant chemotherapy for p-stage I non-small cell lung cancer (4th cooperative study). [abstract]. Lung Cancer 41 Suppl 2 (2003) S54 AO-180
41. Kato H., Ichinose Y., Ohta M., et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. New Engl J Med 350 (2004) 1713-1721
42. Ueda H., Sakada T., Kuwahara M., and Motohiro A. A small randomized phase III single-center trial on postoperative UFT administration in patients with completely resected non-small cell lung cancer. Anti-Cancer Drugs 15 (2004) 29-33
43. Nakagawa M., Tanaka F., Tsubota N., et al. A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I non-small-cell lung cancer. the West Japan Study Group for Lung Cancer Surgery (WJSG)-the 4th study. Ann Oncol 16 (2005) 75-80
44. Waller D., Peake M.D., Stephens R.J., et al. Chemotherapy for patients with non-small cell lung cancer. the surgical setting of the Big Lung Trial. Eur J Cardio-Thorac Surg 26 (2004) 173-182
45. Wheatley K. Understanding meta-analysis. Evid Based Oncol 2 (2001) 116-122
46. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy for non-small cell lung cancer. The Cochrane Library, Issue 1 (2005), Wiley, Chichester
47. Douillard J.Y., Rosell R., Delena M., Legroumellec A., Torres A., Carpagano F., and Adjuvant Navelbine International Trialist Association. ANITA: Phase III adjuvant vinorelbine and cisplatin versus observation in completely resected non-small-cell lung cancer patients: Final results after 70-month median follow-up. [abstract]. J Clin Oncol 23 (2005) A7013
48. Douillard JY, Rosell R, Delena M, Legroumellec A, Torres A, Carpagano F. ANITA: Phase III adjuvant vinorelbine and cisplatin versus observation in completely resected non-small-cell lung cancer patients: Final results after 70-month median follow-up. On behalf of the Adjuvant Navelbine International Trialist Association [slide presentation on the Internet]. 2005 [cited 2005 Jun 28]. Available from: http://www.asco.org/ac/1,1003,_12-002511-00_18-0034-00_19-001684,00.asp.
49. PORT Meta-Analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer. systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 352 (1998) 257-263
50. Burdett S., Stewart L., and PORT Meta-analysis Group. Postoperative radiotherapy in non-small-cell lung cancer. update of an individual patient data meta-analysis. Lung Cancer 47 (2005) 81-83
51. Dautzenberg B., Arriagada R., Chammard A.B., et al. A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma. Cancer 86 (1999) 265-273